Table 3.
Outcomes of patients with AML treated with venetoclax combination strategies according to TP53 mutation status.
| Study | No1 of pts6 | Type of AML2 | Pts6 with mutated TP53 (%) | Type of treatment | Overall Response | Duration of response | Overall survival |
|---|---|---|---|---|---|---|---|
| No of patients (%) | Median time (months/range) | Median time (months/range) | |||||
| Di Nardo et al. (64) | 145 | 145 (100%) de novo AML2 | 36 (25) | 73 (51%) pts6 received VEN3 plus DAC4; 72 (49%) VEN plus AZA5 | 17 (47) | 5.2 (1.2–9.4) | 7.2 (3.7–NR11) |
| Bejar et al. (47) | 31 | 15 (49%) de novo AML2; 16 (51%) R/R8 AML2 | 31(100) | 28 (90%) pts6 received VEN3 plus DAC4; 3 (10%) VEN3 plus AZA5 | 16 (52) 67% in de novo AML2 vs. 38% in R/R8 AML2 (p = 0.01) |
NR7 | NR7 |
| Shoulker et al. (70) | 69 | 36 (52%) de novo AML2; 33 (48%) R/R8 AML2 | 69 (100) | 60 (87%) pts6 received VEN3 plus DAC4 or AZA5; 2 (3%) VEN3 plus FLAG-ida9; 3 (4%) VEN3 plus low dose Ara-C10; 5 (6%) VEN3 plus CPX-351 | 25 (36) 47% in de novo AML2 vs. 24% in R/R8 AML2 |
6.4 months in de novo AML2 vs. 3.6 months in R/R8 AML2 | 3.6 months in de novo AML2 vs. 2.5 months in R/R8 AML2 |
1No, number; 2AML, acute myeloid leukemia; 3VEN, venetoclax; 4DAC, decitabine; 5AZA, azacitidine; 6pts, patients; 7NR, not reported; 8R/R, relapsed/refractory; 9FLAG-ida, fludarabine, cytarabine, G-CSF, idarubicin; 10ARA-C, cytarabine; 11NR, not reached.